Navigation Links
Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
Date:1/25/2013

CHAPEL HILL, N.C., Jan. 25, 2013 /PRNewswire/ -- In order for a new product to gain market foothold in today's competitive pharmaceutical industry, executives must understand where and when to invest in key launch activities. At the same time, product launch leadership has to balance the goals of containing expenditures and generating a successful launch.

To help launch leaders understand effective spend levels for pre-launch and launch activities, research and benchmark consulting firm Best Practices, LLC has published a new study that sheds light on investment levels and frequency across 12 key marketing, education, and payer activities. The study includes overall investment benchmarks by different product types for launch year and each of the three years prior to launch.

The report, "New Product Launch Spend: What it Takes to Win in the U.S. Market" will help leaders in the pharmaceutical sector develop effective launch and pre-launch activity budgets to support successful U.S market entry for new products. The study provides benchmarks that can serve as a reference for brand and launch leaders as they develop budget strategies and allocate funds for new brands.

Key topics covered in the study include:

  • Average Cost: Industry average cost for new pharmaceutical product launch
  • Primary/Specialty Comparison: Cost comparison for specialty versus primary products
  • Budget Allocation: Percentage of budget allocated to 12 key marketing, education and
    market access activities during and prior to launch
  • Activities Timing: Timing for conducting promotional and educational launch activities
  • Future Allocation Trends: Launch activities expected to gain a greater share of the budget in the coming 24-36 months, and activities expected to receive reduced share

The 67-page report is based on a benchmarking study that included 27 brand and marketing executives at 23 leading biopharmaceutical companies. Vice Presidents and Directors make up more than three-quarters of the study's participants and more than half work within marketing functions or departments.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1198.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
2. New Study Introduces Valuable Tool to Aid Doctors and Patients in Choosing Successful Outcomes for Cheek Rejuvenation
3. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
4. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
5. BioDelivery Sciences Announces Completion of BNX Safety Study
6. Harris Poll Study Links Emotional Connection to Physicians Trust in Pharmaceutical Products
7. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
8. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
9. New Study Shows Promise For Women Needing Mesh-Augmented Pelvic Organ Prolapse (POP) Repair
10. BodyMedia Collaborates on Federal Health Research Study
11. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
Breaking Medicine News(10 mins):